INS and Hypoglycemia: Evidence suggests that hypoglycemia is more common in individuals treated with premixed and bolus, and weight gain is more common in those treated with bolus; while in patients treated with BOT, fewer adverse effects were observed compared with those treated with premixed or bolus insulin [34].